Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as rheumatoid arthritis, psoriasis, atopic dermatitis, and inflammatory bowel disease. Several small-molecule JAK inhibit...

Full description

Bibliographic Details
Main Authors:	Taylor, PC, Choy, E, Baraliakos, X, Szekanecz, Z, Xavier, RM, Isaacs, JD, Strengholt, S, Parmentier, JM, Lippe, R, Tanaka, Y
Format:	Journal article
Language:	English
Published:	Oxford University Press 2023

Similar Items

Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders
by: Robert Roskoski, Jr.
Published: (2022-09-01)

Itch and Janus Kinase Inhibitors
by: Yujin Han, et al.
Published: (2023-02-01)

Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways
by: Brandon Johnson, et al.
Published: (2024-09-01)

Commentary: Janus kinase inhibitors and their use in autoimmune ocular inflammatory disorders
by: Mayur R Moreker
Published: (2020-01-01)

Janus kinase inhibitors: jackpot or potluck?
by: Pavithran Keechilat, et al.
Published: (2012-06-01)

Janus Kinase Inhibitors and Cell Therapy
by: Amer Assal, et al.
Published: (2021-08-01)

A review of Janus kinase inhibitors for the treatment of Covid-19 pneumonia
by: Yoshiya Tanaka
Published: (2023-01-01)

Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects
by: E. L. Nasonov, et al.
Published: (2019-03-01)

Acneiform Lesions but not Acne after Treatment with Janus Kinase Inhibitors: Diagnosis and Management of Janus Kinase-acne
by: Fabienne Ballanger, et al.
Published: (2023-06-01)

Janus kinase inhibitors in the treatment of psoriatic arthritis
by: E. Yu. Loginova, et al.
Published: (2022-02-01)

Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis
by: Vishal R. Tandon, et al.
Published: (2022-07-01)

Janus Kinase inhibitors in dermatology: a review
by: Bárbara Vieira-Granja, et al.
Published: (2023-01-01)

Janus Kinase Inhibitors in the Treatment of Alopecia Areata
by: Athanasios J. Stefanis
Published: (2023-02-01)

Janus kinase inhibitors in autoimmune bullous diseases
by: Dawei Huang, et al.
Published: (2023-07-01)

Janus kinase inhibitors in immunoinflammatory rheumatic diseases
by: Evgeny L. Nasonov
Published: (2022-06-01)

Janus kinase inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism?
by: Yachar Dawudi, et al.
Published: (2025-01-01)

Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus
by: Huo R, et al.
Published: (2023-04-01)

The Upadacitinib - New Janus Kinase Inhibitor - Literature Review
by: Michalina Grzelka, et al.
Published: (2024-08-01)

Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
by: Izabella Ryguła, et al.
Published: (2023-12-01)

Janus kinase inhibitors: between prescription authorization and reimbursability
by: F.R. Spinelli, et al.
Published: (2023-12-01)

Bullous pemphigoid treated with Janus kinase inhibitor upadacitinib
by: David Nash, BHSc, et al.
Published: (2023-02-01)

Janus kinase inhibitors - their current applications and future prospects
by: Natalia Wierzbowska, et al.
Published: (2022-09-01)

Role of janus kinase inhibitors in the treatment of alopecia areata
by: Triyangkulsri K, et al.
Published: (2018-07-01)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
by: Singer J, et al.
Published: (2016-08-01)

Clinician and patient views on janus kinase inhibitors in the treatment of inflammatory arthritis: a mixed methods study
by: Savia de Souza, et al.
Published: (2024-01-01)

EMERGING USE OF JANUS KINASE INHIBITORS FOR ORAL LICHEN PLANUS
by: Mihaela Paula Toader, et al.
Published: (2024-06-01)

Janus kinase inhibitors are potential therapeutics for amyotrophic lateral sclerosis
by: Peter J. Richardson, et al.
Published: (2023-10-01)

The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current Insights
by: Eric Toussirot
Published: (2022-02-01)

In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones
by: Kamonpan Sanachai, et al.
Published: (2023-01-01)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
by: Ulrike Blume-Peytavi, et al.
Published: (2015-04-01)

A novel treatment for psoriatic arthritis: Janus kinase inhibitors
by: Miao Chen, et al.
Published: (2020-04-01)

Molecular dissection of Janus kinases as drug targets for inflammatory diseases
by: Sunghark Kwon
Published: (2022-12-01)

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System
by: Satoshi Kubo, et al.
Published: (2018-06-01)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
by: Dionysis Nikolopoulos, et al.
Published: (2023-06-01)

Cardiovascular safety of Janus kinase inhibitors in inflammatory bowel disease: a systematic review and network meta-analysis
by: Huibin Yang, et al.
Published: (2025-12-01)

Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
by: Juqi Zhang, et al.
Published: (2023-06-01)

Janus Kinase Inhibitors as Successful Treatment Alternative in Dupilumab-Induced Psoriasis
by: Lina Weiss, et al.
Published: (2024-06-01)

Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses
by: Qingying He, et al.
Published: (2024-02-01)

RUSSIAN AND INTERNATIONAL EXPERIENCE IN THE APPLICATION OF THE JANUS-KINASES INHIBITOR IN RHEUMATOID ARTHRITIS
by: D. E. Karateev, et al.
Published: (2017-05-01)

Refractory mogamulizumab-associated rash responding to an oral Janus kinase inhibitor
by: Carine M. Lama, MS, et al.
Published: (2023-08-01)